日本語English简体中文 繁體中文

01093 石药集团CSPC PHARMA香港联合交易所

帖子 36 条

石药集团(01093)基本信息

代码
01093
公司名称
石药集团
当地名称
CSPC PHARMA
市场
香港联合交易所
股价
8.53 港元 -0.10 (-1.10%) 11月11日 收盘价

股价数据来自 Yahoo! Finance,可能有延迟。交易前请自行确认最新价格。

石药集团(01093)股价走势

石药集团于2026年11月11日收盘价为8.53 港元,较1个月前−6.1%,较1年前+12.8%。

2026-10-15 事業の状況 VOLUNTARY ANNOUNCEMENT - SYS6062 (ANTIBODY-DRUG CONJUGATE) OBTAINS C… / 事業の状況 VOLUNTARY ANNOUNCEMENT - SYS6088 INJECTION (A TRI-SPECIFIC ANTIBODY)… / 株式報酬制度 VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2…2026-10-16 株式報酬制度 VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2…2026-10-20 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYH2083 EYE DROPS…2026-10-22 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2066 FOR THE … / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE…2026-10-23 事業の状況 VOLUNTARY ANNOUNCEMENT - BATOCLIMAB INJECTION (SUBCUTANEOUS INJECTIO…2026-10-26 事業の状況 VOLUNTARY ANNOUNCEMENT - UPDATED OVERALL SURVIVAL (OS) RESULTS FROM … / 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE III CLINICAL STUDY OF …2026-10-27 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF… / 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF…2026-10-28 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6077 INJECTION… / 子会社の決算 UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL …2026-10-30 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6043 FOR TH…2026-11-02 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6057 (RECOMBIN… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6052 (RECOM… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF PRUSOGLIPTIN TA…2026-11-03 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2072 TABLETS … / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6088 INJECT…2026-11-05 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6062 FOR TH…2026-11-06 取締役会の開催日 DATE OF BOARD MEETING / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6055 INJECT… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH9061 FOR THE …9.07 港元7.85 港元10月12日11月11日
股价5日均线25日均线恒生指数公告
1个月最高9.07 港元10月13日
1个月最低7.85 港元11月3日
较1周前+2.0%较11月4日
较1个月前−6.1%较10月9日

如果1个月前买入1万港元,现在价值9,452 港元(−5.5%)。仅按股价计算,不含股息与手续费。

同期恒生指数涨跌+0.2%,本股为−5.5%。

最近10个交易日收盘价

日期收盘价涨跌涨跌幅
11月11日(周三)8.53 港元−0.10−1.10%
11月10日(周二)8.63 港元+0.20+2.31%
11月9日(周一)8.43 港元−0.02−0.24%
11月6日(周五)8.45 港元−0.13−1.52%
11月5日(周四)8.58 港元+0.22+2.63%
11月4日(周三)8.36 港元+0.51+6.50%
11月3日(周二)7.85 港元−0.04−0.57%
11月2日(周一)7.90 港元+0.03+0.38%
10月30日(周五)7.87 港元−0.17−2.18%
10月29日(周四)8.04 港元+0.07+0.88%
2026-10-08 事業の状況 VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL STUDY OF SYS6002…2026-10-15 事業の状況 VOLUNTARY ANNOUNCEMENT - SYS6062 (ANTIBODY-DRUG CONJUGATE) OBTAINS C… / 事業の状況 VOLUNTARY ANNOUNCEMENT - SYS6088 INJECTION (A TRI-SPECIFIC ANTIBODY)… / 株式報酬制度 VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2…2026-10-16 株式報酬制度 VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2…2026-10-20 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYH2083 EYE DROPS…2026-10-22 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2066 FOR THE … / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE…2026-10-23 事業の状況 VOLUNTARY ANNOUNCEMENT - BATOCLIMAB INJECTION (SUBCUTANEOUS INJECTIO…2026-10-26 事業の状況 VOLUNTARY ANNOUNCEMENT - UPDATED OVERALL SURVIVAL (OS) RESULTS FROM … / 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE III CLINICAL STUDY OF …2026-10-27 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF… / 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF…2026-10-28 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6077 INJECTION… / 子会社の決算 UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL …2026-10-30 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6043 FOR TH…2026-11-02 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6057 (RECOMBIN… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6052 (RECOM… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF PRUSOGLIPTIN TA…2026-11-03 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2072 TABLETS … / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6088 INJECT…2026-11-05 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6062 FOR TH…2026-11-06 取締役会の開催日 DATE OF BOARD MEETING / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6055 INJECT… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH9061 FOR THE …10.07 港元7.85 港元8月11日11月11日
股价5日均线25日均线恒生指数公告
3个月最高10.07 港元9月30日
3个月最低7.85 港元11月3日
较1个月前−6.1%较10月9日
较3个月前−2.0%较8月11日

如果3个月前买入1万港元,现在价值9,805 港元(−2.0%)。仅按股价计算,不含股息与手续费。

同期恒生指数涨跌−5.2%,本股为−2.0%。

最近10个交易日收盘价

日期收盘价涨跌涨跌幅
11月11日(周三)8.53 港元−0.10−1.10%
11月10日(周二)8.63 港元+0.20+2.31%
11月9日(周一)8.43 港元−0.02−0.24%
11月6日(周五)8.45 港元−0.13−1.52%
11月5日(周四)8.58 港元+0.22+2.63%
11月4日(周三)8.36 港元+0.51+6.50%
11月3日(周二)7.85 港元−0.04−0.57%
11月2日(周一)7.90 港元+0.03+0.38%
10月30日(周五)7.87 港元−0.17−2.18%
10月29日(周四)8.04 港元+0.07+0.88%
2026-10-08 事業の状況 VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL STUDY OF SYS6002…2026-10-15 事業の状況 VOLUNTARY ANNOUNCEMENT - SYS6062 (ANTIBODY-DRUG CONJUGATE) OBTAINS C… / 事業の状況 VOLUNTARY ANNOUNCEMENT - SYS6088 INJECTION (A TRI-SPECIFIC ANTIBODY)… / 株式報酬制度 VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2…2026-10-16 株式報酬制度 VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2…2026-10-20 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYH2083 EYE DROPS…2026-10-22 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2066 FOR THE … / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE…2026-10-23 事業の状況 VOLUNTARY ANNOUNCEMENT - BATOCLIMAB INJECTION (SUBCUTANEOUS INJECTIO…2026-10-26 事業の状況 VOLUNTARY ANNOUNCEMENT - UPDATED OVERALL SURVIVAL (OS) RESULTS FROM … / 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE III CLINICAL STUDY OF …2026-10-27 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF… / 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF…2026-10-28 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6077 INJECTION… / 子会社の決算 UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL …2026-10-30 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6043 FOR TH…2026-11-02 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6057 (RECOMBIN… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6052 (RECOM… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF PRUSOGLIPTIN TA…2026-11-03 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2072 TABLETS … / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6088 INJECT…2026-11-05 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6062 FOR TH…2026-11-06 取締役会の開催日 DATE OF BOARD MEETING / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6055 INJECT… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH9061 FOR THE …10.07 港元6.65 港元5月11日11月11日
股价25日均线75日均线恒生指数公告
6个月最高10.07 港元9月30日
6个月最低6.65 港元6月25日
较3个月前−2.0%较8月11日
较6个月前+4.0%较5月11日

如果6个月前买入1万港元,现在价值10,402 港元(+4.0%)。仅按股价计算,不含股息与手续费。

同期恒生指数涨跌−7.9%,本股为+4.0%。

每月收盘价

月份月末收盘价月涨跌幅
2026年11月8.53 港元+8.5%
2026年10月7.87 港元−21.9%
2026年9月10.07 港元+9.0%
2026年8月9.24 港元+7.7%
2026年7月8.58 港元+23.1%
2026年6月6.97 港元−7.1%
2026年5月7.50 港元−10.8%
2026-10-08 事業の状況 VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL STUDY OF SYS6002…2026-10-15 事業の状況 VOLUNTARY ANNOUNCEMENT - SYS6062 (ANTIBODY-DRUG CONJUGATE) OBTAINS C… / 事業の状況 VOLUNTARY ANNOUNCEMENT - SYS6088 INJECTION (A TRI-SPECIFIC ANTIBODY)… / 株式報酬制度 VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2…2026-10-16 株式報酬制度 VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2…2026-10-20 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYH2083 EYE DROPS…2026-10-22 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2066 FOR THE … / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE…2026-10-23 事業の状況 VOLUNTARY ANNOUNCEMENT - BATOCLIMAB INJECTION (SUBCUTANEOUS INJECTIO…2026-10-26 事業の状況 VOLUNTARY ANNOUNCEMENT - UPDATED OVERALL SURVIVAL (OS) RESULTS FROM … / 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE III CLINICAL STUDY OF …2026-10-27 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF… / 事業の状況 VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF…2026-10-28 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6077 INJECTION… / 子会社の決算 UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL …2026-10-30 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6043 FOR TH…2026-11-02 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6057 (RECOMBIN… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6052 (RECOM… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF PRUSOGLIPTIN TA…2026-11-03 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2072 TABLETS … / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6088 INJECT…2026-11-05 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6062 FOR TH…2026-11-06 取締役会の開催日 DATE OF BOARD MEETING / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6055 INJECT… / 事業の状況 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH9061 FOR THE …10.69 港元6.65 港元11月11日11月11日
股价25日均线75日均线恒生指数公告
52周最高10.69 港元1月29日
52周最低6.65 港元6月25日
年初至今+1.1%较12月31日
距52周最高−20.2%1月29日

如果1年前买入1万港元,现在价值11,283 港元(+12.8%)。仅按股价计算,不含股息与手续费。

同期恒生指数涨跌−8.9%,本股为+12.8%。

每月收盘价

月份月末收盘价月涨跌幅
2026年11月8.53 港元+8.5%
2026年10月7.87 港元−21.9%
2026年9月10.07 港元+9.0%
2026年8月9.24 港元+7.7%
2026年7月8.58 港元+23.1%
2026年6月6.97 港元−7.1%
2026年5月7.50 港元−10.8%
2026年4月8.41 港元−7.6%
2026年3月9.10 港元−8.1%
2026年2月9.90 港元+3.1%
2026年1月9.60 港元+13.7%
2025年12月8.44 港元+6.7%
2025年11月7.91 港元+3.4%
11.19 港元4.37 港元2023年11月13日2026年11月11日
股价13周均线26周均线恒生指数
3年最高11.19 港元2025年9月1日
3年最低4.37 港元2025年1月6日
年化收益率+7.6%
最大回撤−40.2%

如果3年前买入1万港元,现在价值12,453 港元(+24.5%)。仅按股价计算,不含股息与手续费。

同期恒生指数涨跌+39.3%,本股为+24.5%。

每年收盘价

年份年末收盘价年涨跌幅
2026(年初至今)8.53 港元+1.1%
2025年8.44 港元―
11.19 港元4.37 港元2021年11月15日2026年11月11日
股价13周均线26周均线恒生指数
5年最高11.19 港元2025年9月1日
5年最低4.37 港元2025年1月6日
年化收益率+0.5%
最大回撤−56.6%

如果5年前买入1万港元,现在价值10,277 港元(+2.8%)。仅按股价计算,不含股息与手续费。

同期恒生指数涨跌−2.9%,本股为+2.8%。

每年收盘价

年份年末收盘价年涨跌幅
2026(年初至今)8.53 港元+1.1%
2025年8.44 港元―
12.79 港元0.45 港元2003年6月1日2026年11月11日
股价1年均线2年均线恒生指数
上市以来最高12.79 港元2018年5月
上市以来最低0.45 港元2006年7月
全部期间涨跌幅+524.0%较2003年6月
年化收益率+8.1%

如果2003年6月买入1万港元,现在价值62,399 港元(+524.0%)。仅按股价计算,不含股息与手续费。

同期恒生指数涨跌+122.9%,本股为+524.0%。

每年收盘价

年份年末收盘价年涨跌幅
2026(年初至今)8.53 港元+1.1%
2025年8.44 港元+77.3%
2024年4.76 港元−34.4%
2023年7.26 港元−11.5%
2022年8.20 港元−3.2%
2021年8.47 港元+6.5%
2020年7.95 港元−17.8%
2019年9.68 港元+64.4%
2018年5.89 港元−28.4%
2017年8.22 港元+90.6%
2016年4.31 港元+4.6%
2015年4.13 港元+15.8%
2014年3.56 港元+11.8%
2013年3.19 港元+174.6%
2012年1.16 港元+30.3%
2011年0.89 港元−60.6%
2010年2.26 港元+0.7%
2009年2.25 港元+58.4%
2008年1.42 港元−6.2%
2007年1.51 港元+163.5%
2006年0.57 港元−8.3%
2005年0.63 港元−41.5%
2004年1.07 港元−17.1%
2003年1.29 港元―

日线・周线・月线收盘价(Yahoo! Finance,已按股票拆分调整,不含股息)。“全部”为Yahoo可提供的范围(2003年6月起)。投资判断请以最新数据为准。

帖子

本留言板与日文版、英文版共用。可以用中文、日文或英文发帖。

No.36 公告 2026/11/06 20:05
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH9061 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
删除
No.35 公告 2026/11/06 20:03
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6055 INJECTION FOR THE TREATMENT OF RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
删除
No.34 公告 2026/11/06 20:01
取締役会の開催日
DATE OF BOARD MEETING
删除
No.33 公告 2026/11/05 19:23
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6062 FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
删除
No.32 公告 2026/11/03 19:26
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6088 INJECTION FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
删除
No.31 公告 2026/11/03 19:24
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2072 TABLETS FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION AND RESISTANT HYPERTENSION OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
删除
No.30 公告 2026/11/02 19:48
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF PRUSOGLIPTIN TABLETS IN COMBINATION WITH DAPAGLIFLOZIN TABLETS AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS ACHIEVES POSITIVE TOPLINE RESULTS
删除
No.29 公告 2026/11/02 19:45
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6052 (RECOMBINANT HERPES ZOSTER VIRUS VACCINE (CHO CELLS)) OFFICIALLY INITIATED IN CHINA
删除
No.28 公告 2026/11/02 19:43
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6057 (RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS VACCINE (CHO CELLS)) OFFICIALLY INITIATED IN CHINA
删除
No.27 公告 2026/10/30 19:33
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL OF SYS6043 FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
删除
No.26 公告 2026/10/28 19:23
子会社の決算
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026
删除
No.25 公告 2026/10/28 19:22
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6077 INJECTION FOR THE TREATMENT OF ADVANCED MALIGNANT TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
删除
No.24 公告 2026/10/27 19:46
事業の状況
VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF SYS6043 (B7-H3 ADC) FOR THE TREATMENT OF ADVANCED BREAST CANCER PRESENTED AS A RAPID ORAL PRESENTATION AT THE ESMO CONGRESS 2026
删除
No.23 公告 2026/10/27 19:45
事業の状況
VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE I/II CLINICAL STUDY OF ANTI-PD-1/IL-15 BIFUNCTIONAL FUSION PROTEIN SYS6090 (JMT108) MONOTHERAPY IN ADVANCED SOLID TUMOURS PRESENTED AS A RAPID ORAL PRESENTATION AT THE ESMO CONGRESS 2026
删除
No.22 公告 2026/10/26 20:26
事業の状況
VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE III CLINICAL STUDY OF ANBENITAMAB IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE FIRST-LINE TREATMENT OF HER2-POSITIVE ADVANCED BREAST CANCER PRESENTED AS A PROFFERED PAPER PRESENTATION AT THE ESMO CONGRESS 2026 AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
删除
No.21 公告 2026/10/26 20:23
事業の状況
VOLUNTARY ANNOUNCEMENT - UPDATED OVERALL SURVIVAL (OS) RESULTS FROM A PHASE III CLINICAL STUDY OF ANBENITAMAB FOR THE TREATMENT OF HER2-POSITIVE ADVANCED GASTRIC CANCER/GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA PRESENTED AS A RAPID ORAL PRESENTATION AT THE ESMO CONGRESS 2026
删除
No.20 公告 2026/10/23 09:00
事業の状況
VOLUNTARY ANNOUNCEMENT - BATOCLIMAB INJECTION (SUBCUTANEOUS INJECTION) OBTAINS DRUG REGISTRATION CERTIFICATE FROM THE NMPA
删除
No.19 公告 2026/10/22 19:31
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE FIRST-LINE TREATMENT OF UNRESECTABLE RECURRENT OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER OFFICIALLY INITIATED IN CHINA
删除
No.18 公告 2026/10/22 19:26
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2066 FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION OFFICIALLY INITIATED IN CHINA
删除
No.17 公告 2026/10/20 19:11
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYH2083 EYE DROPS FOR THE TREATMENT OF DRY EYE DISEASE OFFICIALLY INITIATED IN CHINA
删除
No.16 公告 2026/10/16 19:06
株式報酬制度
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
删除
No.15 公告 2026/10/15 19:00
株式報酬制度
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2018 SHARE AWARD SCHEME
删除
No.14 公告 2026/10/15 18:53
事業の状況
VOLUNTARY ANNOUNCEMENT - SYS6088 INJECTION (A TRI-SPECIFIC ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
删除
No.13 公告 2026/10/15 18:15
事業の状況
VOLUNTARY ANNOUNCEMENT - SYS6062 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
删除
No.12 公告 2026/10/08 19:22
事業の状況
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL STUDY OF SYS6002 AS MONOTHERAPY FOR THE TREATMENT OF ADVANCED CERVICAL CANCER PRESENTED AS A RAPID ORAL PRESENTATION AT THE 2026 ANNUAL GLOBAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY (IGCS 2026)
删除
No.11 公告 2026/10/05 19:50
事業の状況
VOLUNTARY ANNOUNCEMENT - LATEST UPDATES FROM 8 CLINICAL TRIALS TO BE PRESENTED AT THE ESMO CONGRESS 2026
删除
No.10 公告 2026/09/30 21:06
事業の状況
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL STUDY OF EFMEDAGLUTIDE ALFA INJECTION IN COMBINATION WITH METFORMIN IN CHINESE ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS PRESENTED IN A SHORT ORAL DISCUSSION AT THE 62ND ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD 2026)
删除
No.9 公告 2026/09/29 19:03
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE IB CLINICAL TRIAL OF JMT206 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OVERWEIGHT OR OBESITY OFFICIALLY INITIATED AT THE FIRST STUDY CENTRE IN CHINA
删除
No.8 公告 2026/09/29 19:00
事業の状況
VOLUNTARY ANNOUNCEMENT - RECOMBINANT HERPES ZOSTER VACCINE (SYS6052) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
删除
No.7 公告 2026/09/28 19:08
事業の状況
VOLUNTARY ANNOUNCEMENT - SYS6077 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
删除
No.6 公告 2026/09/24 21:08
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF BECOTATUG (JMT101) IN COMBINATION WITH OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NSCLC HARBOURING EGFR EXON 20 INSERTION MUTATIONS ACHIEVES POSITIVE TOPLINE RESULTS
删除
No.5 公告 2026/09/24 18:00
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE TREATMENT OF ADVANCED BREAST CANCER OFFICIALLY INITIATED IN CHINA
删除
No.4 公告 2026/09/17 19:02
中間報告書
2026 INTERIM REPORT
删除
No.3 公告 2026/09/16 19:37
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2069 INJECTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN ADULT PATIENTS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA
删除
No.2 公告 2026/09/15 19:01
事業の状況
VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPA IN CHINA FOR THE TREATMENT OF PATIENTS WITH ACTIONABLE GENOMIC ALTERATION-NEGATIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
删除
No.1 公告 2026/09/14 18:31
事業の状況
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL DATA OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF SYSTEMIC TREATMENT-NAIVE, ACTIONABLE GENOMIC ALTERATION-NEGATIVE ADVANCED NSCLC ORALLY PRESENTED AT THE 2026 WORLD CONFERENCE ON LUNG CANCER (WCLC)
删除

在石药集团股吧发帖

删除帖子时需要此密码,请妥善保管。
发帖即表示同意使用规则(日文),内容由发帖人自行负责。

更多中文版中国股票

中国股票留言板:有中文版的股票

其他中文版留言板